Eplerenone

依普利酮

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug NameEplerenone
Drug Alias Nameeplerenona伊普利酮醛固酮拮抗剂依普利酮Epoxymexrenoneeplerenonum +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMineralocorticoid receptor antagonists
TargetsMineralocorticoid receptor
Therapy Area/IndicationsRejection of renal transplantationFastingMetabolic Syndrome +[17] 
Global Approved IndicationsHypertensionHeart Failure
Approved Indications in ChinaHypertensionHeart Failure
Original Approved Country/TerritoryUnited States
Original Approved Date2002/09/27
Country/TerritoryCzechiaBelgiumCanada +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Interuniversity Cardiology Institute Of The NetherlandsUpjohn Us 2 LlcUniversity Medical Center Groningen +[13] 
Inactive CompaniesViatrisInstitut National De La Santé Et De La Recherche Médicale, France U979Radboud University Medical Center +[13] 
Active IndicationsEssential HypertensionHypertensionMyocardial Infarction +[8] 
Inactive IndicationsRejection of renal transplantationFastingMetabolic Syndrome +[9] 

Other Information

ATC CodeC03DA04
Related LinksWikipediaDrugBankKEGG